Business Context and Reporting Period
Company: Fortress Biotech, Inc. (FBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Fortress is a biopharmaceutical company focused on acquiring and advancing assets through a network of subsidiaries and partner companies. Its primary revenue stream comes from Journey Medical Corporation (Journey), a partner company commercializing dermatology products (e.g., Qbrexza, Accutane). The company also develops early-stage product candidates in oncology, infectious disease, and autoimmune diseases through entities like Checkpoint, Mustang, Avenue, and Helocyte.
Key Financial Metrics
| Metric ($ in thousands) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Net Revenue | $14,896 | $17,386 | $27,926 | $29,815 |
| Net Loss (Consolidated) | $(28,824) | $(59,301) | $(67,846) | $(114,446) |
| Net Loss Attributable to Fortress | $(10,948) | $(24,776) | $(26,365) | $(46,313) |
| Net Loss Per Share (Basic/Diluted) | $(0.73) | $(3.65) | $(1.76) | $(7.14) |
| Cash and Cash Equivalents | $76,201 | $78,022 | $76,201 | $78,022 |
| Total Debt (Long-term, net) | $67,007 | $60,856 | $67,007 | $60,856 |
| Accumulated Deficit | $(721,235) | $(680,546) | $(721,235) | $(680,546) |
Note: Cash and Debt figures represent balances as of June 30, 2024, and December 31, 2023 respectively, as comparative period-end balances are not explicitly provided in the text for Q2 2023.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 14% in Q2 2024 compared to Q2 2023, primarily driven by a 12% decrease in product revenue from Journey (specifically Qbrexza and legacy products). Collaboration revenue was zero in Q2 2024 compared to $183,000 in Q2 2023, as the Cyprium/Sentynl agreement revenue was fully recognized in the prior year.
- Expense Reduction: Total operating expenses decreased 37% in Q2 2024. Research and Development (R&D) expenses dropped 61% to $12.7 million, largely due to reduced commercial manufacturing costs for Checkpoint's cosibelimab and workforce reductions at Mustang. Selling, General, and Administrative (SG&A) expenses decreased 15% to $20.8 million due to cost-reduction initiatives at Fortress and Journey.
- Asset Impairment: The company recorded a $2.6 million asset impairment charge in Q2 2024 related to Mustang's leasehold improvements and right-of-use assets following a repurchase of assets from uBriGene. This compares to a $3.1 million impairment in Q2 2023 related to Journey's Ximino intangible assets.
- Debt Restructuring: In July 2024 (subsequent to the reporting period), Fortress entered a new $50 million credit agreement with Oaktree, replacing the prior $50 million note. The new agreement includes a $35 million initial draw and a $15 million accordion feature.
Guidance, Outlook, and Risks
- Liquidity: Management states that current cash and cash equivalents ($76.2 million total, with $38.2 million at the parent level) are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring substantial losses and will require additional financing for future development.
- Dividend Pause: On July 5, 2024, the Board of Directors paused monthly dividend payments on the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock to preserve cash. Dividends will continue to accrue. This pause may impact the company's ability to use Form S-3 shelf registration statements for future equity raises.
- Key Catalysts:
- Checkpoint: FDA accepted the resubmission of the Biologics License Application (BLA) for cosibelimab (cSCC) with a PDUFA date of December 28, 2024.
- Journey: FDA accepted the NDA for DFD-29 (rosacea) with a PDUFA date of November 4, 2024.
- Helocyte: Topline data for the Triplex (CMV vaccine) Phase 2 trial in HIV/CMV co-infected adults is expected in Q4 2024.
- Risks:
- Financing: Reliance on equity and debt markets; potential dilution; inability to raise capital on favorable terms.
- Product Development: High risk of failure in clinical trials; regulatory delays; generic competition for Journey's non-patented products (Accutane, Targadox, Luxamend, Exelderm).
- Legal: Ongoing litigation involving former subsidiary Caelum (UTRF Litigation), for which Fortress has indemnification obligations capped at acquisition proceeds.
- Operational: Dependence on third-party manufacturers and CROs; cybersecurity risks (referencing a prior $9.5 million fraud incident at Journey).
Investor Verification Checklist
- Cash Runway: Verify the specific cash burn rate of the parent company versus consolidated entities to confirm the "12-month" liquidity assertion.
- Debt Covenants: Review the specific financial covenants in the new Oaktree agreement (minimum liquidity of $7.0 million and Journey's minimum net sales test of $50.0 million trailing 12-month) and assess compliance risks.
- Preferred Stock Impact: Confirm the implications of the paused Series A Preferred Stock dividends on the company's ability to access public equity markets via Form S-3.
- Journey Revenue Mix: Analyze the revenue contribution of patent-protected products (Qbrexza, Amzeeq, Zilxi) versus non-patented products to assess exposure to generic competition.
- Mustang Asset Repurchase: Review the details of the uBriGene asset repurchase and the classification of assets held for sale to understand the impact on future R&D capabilities and balance sheet.